NCT06137092 - rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 22, 2023

Primary Completion Date

September 27, 2023

Study Completion Date

September 27, 2023

Conditions

Severe Hemophilia A

Interventions

DRUG

Factor VIII, recombinant human with Fc fusion (rFVIII-Fc)

rFVIII-Fc, IV, 50 units/kg/ single dose, cross-over

Trial Locations (5)

Seyed-Al-Shohada Hospital, Isfahan

Sarvar Clinic, Mashhad

Dastqeib Hospital, Shiraz

Imam Khomeini, Tehran

Mofid Hospital, Tehran